


Receipt of pneumococcal vaccination

Figure 5.1. Percentage of adults aged 65 and over who had ever received a pneumococcal vaccination: United States, 1997– June 2017




NOTES: Data are based on household interviews of a sample of the civilian noninstitutionalized population. The analyses exclude those with unknown pneumococcal vaccination status (about 5% of respondents each year). Advisory Committee on Immunization Practices recommendations regarding who should receive pneumococcal vaccination have changed over the years, and changes in coverage estimates may reflect changes in recommendations (see <https://www.cdc.gov/vaccines/vpd/pneumo/index.html>). Of particular note, beginning in 2014, all adults aged 65 and over are recommended to receive both the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in series (9–11). The NHIS question on receipt of pneumococcal vaccination does not distinguish the type of vaccine received. See [Technical Notes](#) for more details.

DATA SOURCE: NCHS, National Health Interview Survey, 1997–June 2017, Sample Adult Core component.

- For January–June 2017, the percentage of adults aged 65 and over who had ever received a pneumococcal vaccination was 68.0% (95% confidence interval = 66.28%–69.76%), which was higher than but not significantly different from, the 2016 estimate of 66.9%.
- The percentage of adults aged 65 and over who had ever received a pneumococcal vaccination increased from 42.4% in 1997 to 53.1% in 2000, and then increased more slowly to 59.7% in 2013. The percentage of adults aged 65 and over who had ever received a pneumococcal vaccination again increased more rapidly, from 59.7% in 2013 to 68.0% in January–June 2017.

Figure 5.2. Percentage of adults aged 65 and over who had ever received a pneumococcal vaccination, by age group and sex: United States, January–June 2017




NOTES: Data are based on household interviews of a sample of the civilian noninstitutionalized population. The analyses exclude the 3.7% of adults aged 65 and over with unknown pneumococcal vaccination status. Advisory Committee on Immunization Practices recommendations regarding who should receive pneumococcal vaccination have changed over the years, and changes in coverage estimates may reflect changes in recommendations (see <https://www.cdc.gov/vaccines/vpd/pneumo/index.html>). Of particular note, beginning in 2014, all adults aged 65 and over are recommended to receive both the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in series (9–11). The NHIS question on receipt of pneumococcal vaccination does not distinguish the type of vaccine received. See [Technical Notes](#) for more details.

DATA SOURCE: NCHS, National Health Interview Survey, January–June 2017, Sample Adult Core component.

- For both sexes combined, the percentage of adults by age group who had ever received a pneumococcal vaccination was 63.7% for persons aged 65–74 and 74.5%, for persons aged 75 and over.
- For both sexes combined, adults aged 75 and over were more likely than those aged 65–74 to have ever received a pneumococcal vaccination. This pattern held for males and females.
- There was no significant difference in the prevalence of ever receiving a pneumococcal vaccination between men and women in any age group.

Figure 5.3. Percentage of adults aged 65 and over who had ever received a pneumococcal vaccination, by race and ethnicity: United States, January–June 2017



NOTES: Data are based on household interviews of a sample of the civilian noninstitutionalized population. The analyses exclude the 3.7% of adults aged 65 and over with unknown pneumococcal vaccination status. Advisory Committee on Immunization Practices recommendations regarding who should receive pneumococcal vaccination have changed over the years, and changes in coverage estimates may reflect changes in recommendations (see <https://www.cdc.gov/vaccines/vpd/pneumo/index.html>). Of particular note, beginning in 2014, all adults aged 65 and over are recommended to receive both the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in series (9–11). The NHIS question on receipt of pneumococcal vaccination does not distinguish the type of vaccine received. See [Technical Notes](#) for more details.

DATA SOURCE: NCHS, National Health Interview Survey, January–June 2017, Sample Adult Core component.

- The percentage of adults aged 65 and over by race and ethnicity who had ever received a pneumococcal vaccination was 44.7% for Hispanic persons, 73.1% for non-Hispanic white persons, and 55.7% for non-Hispanic black persons.
- Of the three race and ethnicity groups, non-Hispanic white adults were more likely to have ever received a pneumococcal vaccination than non-Hispanic black and Hispanic adults.

Data tables for Figures 5.1–5.3:

Data table for Figure 5.1. Percentage of adults aged 65 and over who had ever received a pneumococcal vaccination: United States, 1997– June 2017

| Year | Crude ¹ percent (95% confidence interval) | Age-adjusted ² percent (95% confidence interval) |
|-------------------|--|---|
| 1997 | 42.4 (40.9–43.9) | 42.6 (41.1–44.1) |
| 1998 | 46.0 (44.5–47.5) | 46.3 (44.8–47.8) |
| 1999 | 49.7 (48.1–51.3) | 49.9 (48.3–51.5) |
| 2000 | 53.1 (51.5–54.7) | 53.4 (51.8–55.0) |
| 2001 | 54.0 (52.4–55.6) | 54.2 (52.6–55.7) |
| 2002 | 56.0 (54.5–57.5) | 56.2 (54.8–57.7) |
| 2003 | 55.6 (54.1–57.1) | 55.7 (54.2–57.1) |
| 2004 | 56.8 (55.3–58.3) | 57.0 (55.5–58.5) |
| 2005 | 56.2 (54.82–57.64) | 56.3 (54.95–57.72) |
| 2006 | 57.1 (55.25–58.88) | 57.2 (55.43–59.04) |
| 2007 | 57.7 (55.68–59.69) | 57.8 (55.78–59.80) |
| 2008 | 59.6 (57.68–61.48) | 59.8 (57.98–61.64) |
| 2009 | 60.6 (58.74–62.51) | 61.0 (59.15–62.79) |
| 2010 | 59.4 (57.61–61.17) | 59.8 (58.02–61.51) |
| 2011 | 62.3 (60.55–63.95) | 62.7 (61.04–64.31) |
| 2012 | 59.9 (58.29–61.49) | 60.4 (58.86–62.01) |
| 2013 | 59.7 (58.02–61.36) | 60.4 (58.77–62.05) |
| 2014 | 61.3 (59.88–62.80) | 62.3 (60.82–63.70) |
| 2015 | 63.5 (62.00–65.05) | 64.1 (62.59–65.57) |
| 2016 | 66.9 (65.47–68.38) | 67.7 (66.30–69.14) |
| January–June 2017 | 68.0 (66.28–69.76) | 68.8 (67.02–70.63) |

¹Crude estimates are presented.

²Estimates are age-adjusted using the projected 2000 U.S. population as the standard population and two age groups: 65–74 and 75 and over.

NOTES: Data are based on household interviews of a sample of the civilian noninstitutionalized population. Beginning with 2012 data, the National Health Interview Survey transitioned to weights derived from the 2010 census. For 2003–2011 data, weights were derived from the 2000 census. In this Early Release, estimates for 2000–2002 were recalculated using weights derived from the 2000 census. For 1997–1999 data, weights were derived from the 1990 census. See [Technical Notes](#) for more details.

DATA SOURCE: NCHS, National Health Interview Survey, 1997–June 2017, Sample Adult Core component.

Data table for Figure 5.2. Percentage of adults aged 65 and over who had ever received a pneumococcal vaccination, by age group and sex: United States, January–June 2017

| Age (years) and sex | Percent | 95% confidence interval |
|--|---------|-------------------------|
| 65–74, total | 63.7 | 61.31–66.08 |
| 65–74, male | 62.0 | 57.92–65.97 |
| 65–74, female | 65.1 | 62.19–68.01 |
| 75 and over, total | 74.5 | 71.20–77.52 |
| 75 and over, male | 74.9 | 69.37–79.94 |
| 75 and over, female | 74.1 | 69.95–77.94 |
| 65 and over (crude ¹), total | 68.0 | 66.28–69.76 |
| 65 and over (crude ¹), male | 67.1 | 64.06–69.97 |
| 65 and over (crude ¹), female | 68.8 | 66.49–71.09 |
| 65 and over (age-adjusted ²), total | 68.8 | 67.02–70.63 |
| 65 and over (age-adjusted ²), male | 68.2 | 65.04–71.20 |
| 65 and over (age-adjusted ²), female | 69.4 | 67.02–71.73 |

¹Crude estimates are presented.

²Estimates are age-adjusted using the projected 2000 U.S. population as the standard population and two age groups: 65–74 and 75 and over.

NOTE: Data are based on household interviews of a sample of the civilian noninstitutionalized population.

DATA SOURCE: NCHS, National Health Interview Survey, January–June 2017, Sample Adult Core component.

Data table for Figure 5.3. Percentage of adults aged 65 and over who had ever received a pneumococcal vaccination, by race and ethnicity: United States, January–June 2017

| Race and ethnicity | Crude ¹ percent (95% confidence interval) | Age-adjusted ² percent (95% confidence interval) |
|--|---|--|
| Hispanic or Latino | 44.7 (36.21–53.44) | 46.2 (37.29–55.22) |
| Not Hispanic or Latino, single race, white | 73.1 (71.35–74.88) | 73.8 (71.96–75.50) |
| Not Hispanic or Latino, single race, black | 55.7 (47.69–63.55) | 57.6 (50.31–64.63) |

¹Crude estimates are presented.

²Estimates are age-adjusted using the projected 2000 U.S. population as the standard population and two age groups: 65–74 and 75 and over.

NOTE: Data are based on household interviews of a sample of the civilian noninstitutionalized population.

DATA SOURCE: NCHS, National Health Interview Survey, January–June 2017, Sample Adult Core component.